tetano
Editor, Senior Moderator
J Dermatol
. 2022 Mar 3.
doi: 10.1111/1346-8138.16347. Online ahead of print.
Three cases of drug-induced hypersensitivity syndrome associated with mRNA-based coronavirus disease 2019 vaccines
Ayumi Korekawa[SUP] 1 [/SUP], Koji Nakajima[SUP] 1 [/SUP], Karen Fukushi[SUP] 1 [/SUP], Hajime Nakano[SUP] 1 [/SUP], Daisuke Sawamura[SUP] 1 [/SUP]
Affiliations
Abstract
Drug-induced hypersensitivity syndrome (DiHS) is a severe drug eruption that can induce reactivation of herpesviruses such as human herpesvirus 6, resulting in symptom flare-up and organ damage. DiHS is known as drug reaction with eosinophilia and systemic symptoms (DRESS) in Europe. We report three cases of DiHS that could have been triggered by mRNA-based coronavirus disease 2019 (COVID-19) vaccines. In these three patients, symptoms of DiHS developed 2-6 days after the first dose of an mRNA-based COVID-19 vaccine. Although there have been no reports of DiHS/DRESS induced by mRNA-based COVID-19 vaccines in domestic and international journals despite the progress in vaccination worldwide, we speculate that mRNA-based COVID-19 vaccines might have triggered the development of DiHS/DRESS in our patients. In the current coronavirus epidemic, it might be important to assess mRNA-based COVID-19 vaccination status and date of vaccination when evaluating a patient with DiHS/DRESS.
Keywords: coronavirus disease 2019; drug-induced hypersensitivity syndrome; human herpesvirus 6; mRNA; vaccine.
. 2022 Mar 3.
doi: 10.1111/1346-8138.16347. Online ahead of print.
Three cases of drug-induced hypersensitivity syndrome associated with mRNA-based coronavirus disease 2019 vaccines
Ayumi Korekawa[SUP] 1 [/SUP], Koji Nakajima[SUP] 1 [/SUP], Karen Fukushi[SUP] 1 [/SUP], Hajime Nakano[SUP] 1 [/SUP], Daisuke Sawamura[SUP] 1 [/SUP]
Affiliations
- PMID: 35243679
- DOI: 10.1111/1346-8138.16347
Abstract
Drug-induced hypersensitivity syndrome (DiHS) is a severe drug eruption that can induce reactivation of herpesviruses such as human herpesvirus 6, resulting in symptom flare-up and organ damage. DiHS is known as drug reaction with eosinophilia and systemic symptoms (DRESS) in Europe. We report three cases of DiHS that could have been triggered by mRNA-based coronavirus disease 2019 (COVID-19) vaccines. In these three patients, symptoms of DiHS developed 2-6 days after the first dose of an mRNA-based COVID-19 vaccine. Although there have been no reports of DiHS/DRESS induced by mRNA-based COVID-19 vaccines in domestic and international journals despite the progress in vaccination worldwide, we speculate that mRNA-based COVID-19 vaccines might have triggered the development of DiHS/DRESS in our patients. In the current coronavirus epidemic, it might be important to assess mRNA-based COVID-19 vaccination status and date of vaccination when evaluating a patient with DiHS/DRESS.
Keywords: coronavirus disease 2019; drug-induced hypersensitivity syndrome; human herpesvirus 6; mRNA; vaccine.